The Nikkei Asian Review explores China’s rapid advances in the field of biotechnology, including gene editing and the use of AI and big data to predict a person’s likelihood of developing a given disease. As Chinese biotech startups push ahead in these areas, venture capital is pouring in from overseas. At the same time, however, scientists and policymakers in developed countries are questioning China’s adherence to ethical standards when it comes to such issues as human trials and access to personal data. READ MORE
Similar Posts:
- Legend Biotech (NASDAQ: LEGN): The J&J Partner Recently Surged on Leaked Data About It’s Multiple Myeloma Treatment
- Asia300 Power Performers: Tech’s Wild Ride (Nikkei Asian Review)
- After Jack: Alibaba Searches for New Growth in the Post-Ma Era (Nikkei Asian Review)
- Huawei Turns to Mobile Chip Rivals to Beat US Pressure (Nikkei Asian Review)
- Asia300: Chinese Companies Face Surging Write-offs (Nikkei Asian Review)
- Lessons From Japan’s Lost Decades for China (Nikkei Asian Review)
- China Scrambles to Stem Manufacturing Exodus as 50 Companies Leave (Nikkei Asian Review)
- China: Innovation Superpower (Wellington Management)
- Asia is Home to 50% of World’s Fastest Growing Companies (Nikkei Asian Review)
- India Moves Up the Ranks of Asia300 Companies (Nikkei Asian Review)
- After a 15-year Hot Streak, Macao’s Casino Owners May Have to Pay Up (Nikkei Asian Review)
- Jollibee’s Big Appetite (Nikkei Asian Review)
- Asian Streaming Services Have Content plus Capital to Edge Netflix & Amazon (Nikkei Asian Review)
- U.S.-China Trade War: The New Long March (Guggenheim Investments)
- US Citizens at Chinese Chip Firms Caught in the Middle of Tech War After New Export Restrictions (SCMP)
